Hinduja Global Solutions limited (HGS) (Listed on NSE & BSE, India), has joined hands with Mumbai-based P.D. Hinduja Hospital & Medical Research Centre for the “Treat to Cure MDR TB” program. This initiative aims to provide treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) patients and address the cause of growing mortality rate due to TB in India.
World Health Organization’s (WHO) Global Tuberculosis Report 2017 revealed that an estimated 10.4 million people fell ill with TB in 2016: 56% of these were in five countries - India, Indonesia, China, the Philippines and Pakistan. In 2016, there were 600,000 new cases with resistance to Rifampicin (RR- TB), the most effective first-line drug of which 490,000 had multidrug resistant TB (MDR-TB). 47% of these cases were in India, China and the Russian Federation. The magnitude of Drug Resistant-TB problem in India has also risen. Currently, WHO estimates incidence of MDR-TB to be around 147,000. This translates to 11 patients per 100,000 population.
HGS’ “Treat to cure MDR TB project“ was initiated in August 2015 with an aim to provide help in diagnosing the disease in its early stages to ensure that the patients receive the right treatment at the right time and are cured successfully. The project includes funding the total cost of the two-year treatment cycle - medicines, labs test and other diagnostic services required by these patients.
Speaking about the program, Smita Gaikwad, Senior Vice President – Global Corporate Communications & CSR, HGS said, “TB needs immediate attention in terms of both diagnosis and treatment, and improved sharing of patient care information. HGS’ Treat to Cure MDR-TB is a positive step taken in the direction of funding proper diagnosis and providing accurate treatment. Our partnership with P.D. Hinduja Hospital & Medical Research Centre will ensure quality care for 100 patients.”
Gautam Khanna, CEO, P.D. Hinduja Hospital & Medical Research Center said, “A large number of patients are found affected by TB, both in India and globally. There is an urgent need for well-equipped organizations and resources that can help us fight TB, one of the most lethal diseases. I am hopeful that our association with HGS will definitely make a difference in treating TB patients in India.”
Dr. Camilla Rodrigues, Consultant Microbiologist & Chairperson - Infection Control Committee, P D Hinduja Hospital & Medical Research Center remarked, “TB is the world’s biggest public health killer and Drug Resistant TB threatens to derail the progress to control it. The treatment cost for each patient is approximately two lakh rupees and HGS’ support is a big help for us.”
A report published by Dr. Zarir F. Udwadia, Consultant Chest Physician at P.D. Hinduja Hospital & Medical Research Centre in 2012 resulted in a nationwide notification of TB as well as a major restructuring in the National TB Control Program in Maharashtra and Bombay Municipal Corporation to enhance case detection and treatment of MDR-TB and XDR-TB. In 2013, Global Health Strategies (GHS) conferred P.D Hinduja Hospital & Medical Research Center with the “1st TB Champions” award for its outstanding contribution to the testing and effective management of the disease.
HGS was recently recognized for its “Treat to Cure MDR-TB” program in the “Concern for Health” category at the ET Now – CSR Leadership Awards 2018.
About Hinduja Global Solutions (HGS):
A global leader in business process management (BPM) and optimizing the customer experience lifecycle, HGS is helping make its clients more competitive every day. HGS combines technology-powered services in automation, analytics and digital with domain expertise focusing on back office processing, contact centers and HRO solutions to deliver transformational impact to clients. Part of the multi-billion dollar conglomerate Hinduja Group, HGS takes a true “globally local” approach, with over 46,000 employees across 69 delivery centers in seven countries making a difference to some of the world’s leading brands across nine key verticals. For the year ended 31st March 2017, HGS had revenues of Rs. 3,711 crore (US$ 555 million).
Log in to https://www.teamhgs.com/ to know how we can help make you more competitive.
About P.D. Hinduja Hospital & Medical Research Centre:
P.D. Hinduja Hospital and Medical Research Center, which started off as a clinic in 1951, is today ranked as one of the leading Multi-Specialty tertiary care hospitals in the country. For over six decades, this institute has worked to ensure that world-class healthcare delivery is provided to all. The hospital has always been an early adopter of technology in delivery of care; being amongst the first few hospitals in the country to have Gama Knife technology, Digital Broadband MRI with ambient themes, True Beam Linear Accelerator and more. The hospital has on-board some of the best nationally and internationally recognized doctors. Quality care being the focus, it was amongst the early few hospitals that has been accredited and certified by NABH, CAP, and ISO. P.D. Hinduja Hospital was also one of the pioneers in its space to launch Care@Home and Short Stay Service in 2007 and 2008 respectively. It continues to partner with leading International Institutes, latest being an arrangement with The Division of AIDS (NIAID, NIH), U.S.A, to establish a center of excellence for infectious disease research in India. For its contribution to quality healthcare delivery, the hospital has also been bestowed with Best Multi-Specialty Hospital awards by different industry bodies. In line with one of its guiding principles “Work to Give”, the hospital runs the Serve with Passion rural health programme, under which free healthcare services are provided to the tribal areas in Maharashtra and Dadra Nagar Haveli.
For further information, please contact:
For Hinduja Global Solutions (HGS):
Smita Gaikwad Thanuja B M
+91 80 46431005 +91 89711 45454
For P.D. Hinduja Hospital & Medical Research Centre:
Dr. Bindu C: +91 22 24447412
Sreehari Nair: +91 22 24447774O